RT Journal Article SR Electronic T1 Development and Validation of the COVID-NoLab and COVID-SimpleLab Risk Scores for Prognosis in 6 US Health Systems JF The Journal of the American Board of Family Medicine JO J Am Board Fam Med FD American Board of Family Medicine SP S127 OP S135 DO 10.3122/jabfm.2021.S1.200464 VO 34 IS Supplement A1 Mark H. Ebell A1 Xinyan Cai A1 Robert Lennon A1 Derjung M. Tarn A1 Arch G. Mainous III A1 Aleksandra E. Zgierska A1 Bruce Barrett A1 Wen-Jan Tuan A1 Kevin Maloy A1 Munish Goyal A1 Alex Krist YR 2021 UL http://www.jabfm.org/content/34/Supplement/S127.abstract AB Purpose: Develop and validate simple risk scores based on initial clinical data and no or minimal laboratory testing to predict mortality in hospitalized adults with COVID-19.Methods: We gathered clinical and initial laboratory variables on consecutive inpatients with COVID-19 who had either died or been discharged alive at 6 US health centers. Logistic regression was used to develop a predictive model using no laboratory values (COVID-NoLab) and one adding tests available in many outpatient settings (COVID-SimpleLab). The models were converted to point scores and their accuracy evaluated in an internal validation group.Results: We identified 1340 adult inpatients with complete data for nonlaboratory parameters and 741 with complete data for white blood cell (WBC) count, differential, c-reactive protein (CRP), and serum creatinine. The COVID-NoLab risk score includes age, respiratory rate, and oxygen saturation and identified risk groups with 0.8%, 11.4%, and 40.4% mortality in the validation group (AUROCC = 0.803). The COVID-SimpleLab score includes age, respiratory rate, oxygen saturation, WBC, CRP, serum creatinine, and comorbid asthma and identified risk groups with 1.0%, 9.1%, and 29.3% mortality in the validation group (AUROCC = 0.833).Conclusions: Because they use simple, readily available predictors, developed risk scores have potential applicability in the outpatient setting but require prospective validation before use.